Khurem became Chief Executive Officer in 2019, bringing more than 20 years of experience in drug development and operational leadership to Gyroscope. He previously served as the Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group.
During his eleven-year tenure at Genentech, Khurem led the commercialization and launch planning of a number of medicines in the Immunology and Opthalomology area and helped move a number of medicines into the pipeline as a member of the Late Stage Portfolio Committee. He also was actively involved in a number of business development assessments for the organization.
Khurem began his career at Aventis in the United Kingdom holding various roles in sales and marketing, including leading several pan-European business initiatives at the European Headquarters in Paris.
Khurem holds a Master’s Degree in Business Administration as well as an Honors degree in Biological Sciences.
Soraya is a Board-certified MD with 20 years of experience in Drug Development across several therapeutic areas, with a focus on gene therapy and she leads the research and development of Gyroscope’s therapeutics pipeline. Between 2017 and March 2019 Soraya served as CEO and CMO of Gyroscope and led the company successfully to clinical stage.
Prior to joining Gyroscope, Soraya served as SVP Chief Medical Officer of Lysogene, a clinical stage biotech developing gene therapy products in rare central nervous system diseases. As a member of the executive team, she contributed to the successful listing of the company on the European Stock Exchange Euronext.
Prior to that Soraya held leadership positions within global research and development at Sanofi. As Development Head for a global gene therapy programme in peripheral artery disease, she led the only phase III gene therapy programme conducted in 30 countries over 5 continents. Subsequently she was appointed Chief Medical Officer of the newly created Ophthalmology Division when Sanofi acquired Biotech Fovea pharmaceuticals where she oversaw the clinical development, regulatory, health economics and programme management. In a broader capacity she took over the overall leadership of the Global Ophthalmology Division where she orientated the Sanofi strategy towards investing in ocular gene therapy, building up a pipeline of in-licensed or internal programs in inherited retinal dystrophies, or more prevalent conditions such as wet AMD, diabetic retinopathy, uveitis and glaucoma.
She holds a Medical Degree from Paris University and specialised in clinical pharmacology and biostatistics.
A proven leader, Mike brings more than 20 years of experience in medical device research and development. His expertise spans the innovation, design, and commercialization of surgical products across multiple markets including ophthalmology, spine, and sports medicine. He founded Orbit Biomedical and also recently served as Director of Cell-Based Product Delivery in Janssen R&D, where he led the development of the surgical instrumentation and procedure for the delivery of a cell product to the subretinal space. Mike has been instrumental in transitioning this technology out of Janssen R&D and into Orbit Biomedical. Prior to Janssen, Mike worked in various roles of increasing responsibility in R&D at Depuy Synthes Spine and played a key role at an early stage spine-related startup in the Philadelphia area, transitioning technology out of Drexel University.
Mike holds a MEng in Bioengineering from the University of California, San Diego and a bachelor’s degree in Engineering Science and Mechanics from Pennsylvania State University. He is an author of multiple manuscripts in the field of biomedical engineering and an inventor on 12 issued patents.
Susan brings more than 20 years of experience in large and small biotech companies and financial institutions, with a special focus on gene therapy and rare disease. Most recently she was founding CEO of Orbit Biomedical (Ambler, PA), prior to which she served as Chief Business Officer of Freeline Therapeutics, a liver-directed gene therapy company (London, UK). Previously, Susan held senior Business Development positions within Alexion (Boston, MA), and senior Business Development and Portfolio Management positions for Serono and Merck Serono (Geneva, Switzerland). Susan launched her career at KPMG and Aberdeen Asset Managers in the UK.
She holds an MA and Ph.D. in molecular biology from the University of Cambridge, UK, and is a previous Fellow of the Securities Institute. She serves on the Scientific Advisory Board of the Swiss SanFilippo Foundation, and on the Development Committee of Christ’s College, Cambridge.
Ashwin has more than 25 years of lab management, business operations, and human resources experience in academia and the biotechnology industry. His diverse experience includes leadership roles in R&D, commercial, and manufacturing, leading culturally diverse teams across global regions including the US, Europe, and Asia.
His R&D teams have supported the filing of more than 70 INDs/CTAs/ED Go NMEs in various therapeutic areas including immunology, ophthalmology, oncology, infectious diseases, and neuroscience.
As a commercial leader, he has built teams to support Pipeline Marketing (for immunology, respiratory, and ophthalmology) and a field based team leading business-to-business discussions on various programs supporting medicines in ophthalmology, rhuematology, and respiratory franchises.
In Human Resources, he has led teams in a global matrix environment, including supporting an 8,500 employee global Biologics manufacturing network. Ashwin’s career has spanned innovative organizations including the University of California, Los Angeles (UCLA), TRW, Amgen, Genentech, Roche, and Juno Therapeutics. More recently he helped build out disruptive start-ups GRAIL, Vitrisa, Allogene, and Sana. He is recognized for his passion to coach and develop people, keeping patients and the unmet need as the guiding compass.
Gyroscope Therapeutics Ltd is developing cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement systemView More +
Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of sustained treatment delivery.View More +